Published on 23 Jun 2021 on Simply Wall St. via Yahoo Finance

When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Turn A Profit?

With the business potentially at an important milestone, we thought we'd take a closer look at Nabriva Therapeutics plc's (NASDAQ:NBRV) future prospects. Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. With the latest financial year loss of US$69m and a trailing-twelve-month loss of US$60m, the US$72m market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which Nabriva Therapeutics will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Check out our latest analysis for Nabriva Therapeutics

Consensus from 3 of the American Pharmaceuticals analysts is that Nabriva Therapeutics is on the verge of breakeven. They expect the company to post a final loss in 2022, before turning a profit of US$398k in 2023. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 66%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.